Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Akero Therapeutics, Inc. - Common Stock (NQ:AKRO)

53.60 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Akero Therapeutics, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
US Stocks Gain; PepsiCo Posts Upbeat Earnings
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 50 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.19% to 33,668.96 while the NASDAQ rose 0.16%... 
Via Benzinga
Topics Stocks
Why Is Akero Therapeutics (AKRO) Stock Down 58% Today?
Akero Therapeutics (stock is falling hard on Tuesday after the company failed to impress AKRO investors with its clinical trial results. 
Via InvestorPlace
Why Akero Therapeutics Lost More Than Half Its Value, And Dragged Down 89bio
Both companies are working on treatments for NASH. But Akero's disappointed in a midstage test. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to dive into the biggest pre-market stock movers with all the most recent news moving shares on Tuesday morning! 
Via InvestorPlace
4 Analysts Have This to Say About Akero Therapeutics
 
Via Benzinga
Akero Therapeutics Inc. (NASDAQ: AKRO) is a Stock Spotlight on 6/9
Via Investor Brand Network
Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and
From Akero Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH
Investor webcast on Tuesday, October 10 at 8:00 a.m. ET to present clinical data 
From Akero Therapeutics
Via GlobeNewswire
Analyst Ratings for Akero Therapeutics
 
Via Benzinga
Analyst Expectations for Akero Therapeutics's Future
 
Via Benzinga
Akero Therapeutics Announces Publication of the Harmony Phase 2b Trial Results in The Lancet Gastroenterology & Hepatology
From Akero Therapeutics
Via GlobeNewswire
7 ‘Strong Buy’ Biotech Stocks to Rejuvenate Your Portfolio
Dive into these seven strong buy biotech stocks, handpicked by Wall Street, to inject vigor into your investment game. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For September 19, 2023
 
Via Benzinga
Akero Therapeutics to Present at Upcoming Healthcare Conferences in September
From Akero Therapeutics
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 28, 2023
 
Via Benzinga
Akero Therapeutics to Report Results of Phase 2b SYMMETRY Study in October 2023
From Akero Therapeutics
Via GlobeNewswire
Over $15.5M Bet On ModivCare? Check Out These 4 Stocks Insiders Are Buying
Although U.S. stocks closed slightly higher on Thursday, there were a few notable insider trades. 
Via Benzinga
Akero Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
From Akero Therapeutics
Via GlobeNewswire
Over $2M Bet On Akero Therapeutics? Check Out These 3 Stocks Insiders Are Buying
Although U.S. stocks closed mixed on Tuesday, there were a few notable insider trades. 
Via Benzinga
Akero Therapeutics Presents Analyses of Phase 2b HARMONY Study at the 2023 International Liver Congress Reinforcing and Characterizing EFX-Related Improvements in Liver Histopathology
Data show changes in non-invasive tests in EFX-treated patients were associated with improvements in NASH histopathology and highlight dose-dependent responses 
From Akero Therapeutics
Via GlobeNewswire
3 Mid Caps You Haven't Heard Of But Need To Know About
Here are three mid-cap stocks that will not have been on the radar for most readers but whose recent performance warrants closer inspection and consideration. 
Via MarketBeat
Akero Therapeutics’ Phase 2b SYMMETRY Cohort D Study Met Safety & Tolerability Endpoints and Showed Adding EFX to GLP-1 Therapy Significantly Improved Non-Invasive Markers of NASH-Related Disease
From Akero Therapeutics
Via GlobeNewswire
Akero Therapeutics to Present Results from Phase 2b Expansion Cohort of SYMMETRY Trial Evaluating Efruxifermin in Combination with GLP-1
Investor webcast on Monday, June 5 at 8:00 a.m. ET to present clinical data 
From Akero Therapeutics
Via GlobeNewswire
Akero Therapeutics to Present at the Jefferies Healthcare Conference
From Akero Therapeutics
Via GlobeNewswire
$9.6M Bet On Energy Transfer? Check Out These 4 Stocks Insiders Are Buying
Although US stocks closed lower on Tuesday, there were a few notable insider trades. 
Via Benzinga
Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering of Common Stock
From Akero Therapeutics
Via GlobeNewswire
Akero Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
From Akero Therapeutics
Via GlobeNewswire
Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH
From Akero Therapeutics
Via GlobeNewswire
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.